- Home
- NEGG vs AMRN Comparison
NEGG vs AMRN Comparison
Compare NEGG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$33.87
HOLD
Current Price
$14.61
Company Overview
Basic Information| Metric | NEGG | AMRN |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | Ireland |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | NEGG | AMRN |
|---|---|---|
| Price | $33.87 | $14.61 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 35.8K | ★ 79.9K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $0.21 | $0.39 |
| 52 Week High | $137.84 | $20.90 |
Technical Indicators
Market Signals| Indicator | NEGG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 43.84 |
| Support Level | $29.87 | $13.63 |
| Resistance Level | $56.73 | $14.55 |
| Average True Range (ATR) | 3.21 | 0.80 |
| MACD | -0.73 | -0.03 |
| Stochastic Oscillator | 16.93 | 22.16 |
Price Performance
Historical Comparison NEGG
AMRN
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.